Andress D L, Maloney N A, Coburn J W, Endres D B, Sherrard D J
J Clin Endocrinol Metab. 1987 Jul;65(1):11-6. doi: 10.1210/jcem-65-1-11.
The bone histology in patients with chronic renal failure and aluminum-related bone disease does not always show the excess accumulation of unmineralized osteoid (matrix) characteristic of osteomalacia. Frequently, bone aluminum accumulation is associated with normal or reduced amounts of unmineralized osteoid and low bone formation and is referred to as aplastic bone disease. In this study, we compared static and dynamic bone histomorphometric parameters and plasma PTH and aluminum levels in 12 patients with osteomalacia and 18 patients with aplastic bone disease who had been receiving dialysis for the same duration to determine if the difference in osteoid accumulation in these 2 lesions might be explained by differences in aluminum accumulation or PTH levels. The stainable bone surface aluminum level was significantly higher in the patients with osteomalacia compared to that in the group with aplastic bone [61 +/- 5% (+/- SEM) vs. 43 +/- 4%; P less than 0.02]. The rates of bone apposition and bone formation were lower in the group with osteomalacia (P less than 0.01). Plasma amino-terminal PTH was not significantly different in the 2 groups. The increment in plasma aluminum levels after a single infusion of deferoxamine was higher in the osteomalacic group than in the aplastic group, suggesting that the patients with osteomalacia accumulated more total body chelatable aluminum than did those with aplastic bone disease during a comparable length of time on dialysis. We conclude that the excess unmineralized osteoid in aluminum-related osteomalacia results from the high rate of total body aluminum accumulation, which directly causes uncoupling of matrix mineralization and matrix production, independent of PTH levels. Patients with aplastic bone disease who have accumulated lesser amounts of total body aluminum fail to develop excess unmineralized osteoid because production and mineralization of matrix are more closely coupled than in the osteomalacic lesion, despite a decline in osteoblast numbers.
慢性肾衰竭及铝相关性骨病患者的骨组织学表现并不总是呈现骨软化症所特有的未矿化类骨质(基质)过度蓄积。通常,骨铝蓄积与未矿化类骨质数量正常或减少以及低骨形成相关,被称为再生障碍性骨病。在本研究中,我们比较了12例骨软化症患者和18例再生障碍性骨病患者的静态和动态骨组织形态计量学参数、血浆甲状旁腺激素(PTH)水平及铝水平,这些患者接受透析的时间相同,以确定这两种病变中类骨质蓄积的差异是否可由铝蓄积或PTH水平的差异来解释。与再生障碍性骨病组相比,骨软化症患者可染色骨表面铝水平显著更高[61±5%(±标准误)对43±4%;P<0.02]。骨软化症组的骨贴附率和骨形成率更低(P<0.01)。两组患者血浆氨基末端PTH无显著差异。单次输注去铁胺后,骨软化症组血浆铝水平的升高高于再生障碍性骨病组,这表明在透析相当长的时间内,骨软化症患者比再生障碍性骨病患者蓄积了更多的全身可螯合铝。我们得出结论,铝相关性骨软化症中过量的未矿化类骨质是由全身铝蓄积率高所致,这直接导致基质矿化与基质产生解偶联,与PTH水平无关。全身铝蓄积量较少的再生障碍性骨病患者不会形成过量的未矿化类骨质,因为尽管成骨细胞数量减少,但与骨软化症病变相比,基质的产生和矿化更紧密地偶联。